CoChat

Tolerability and Pharmacokinetics of Aripiprazole in Children and Adolescents With Psychiatric Disorders: An Open-Label, Dose-Escalation Study

Findling, Robert L., Kauffman, Ralph E., Sallee, Floyd R., Carson, William H., Nyilas, Margaretta, Mallikaarjun, Suresh, Shoaf, Susan E., Forbes, Robert A., Boulton, David W., Pikalov, Andrei · 2008 · Journal of Clinical Psychopharmacology
Cited by 66

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

This multicenter, open-label, sequential-cohort, dose-escalation study explored the tolerability and pharmacokinetics (PK) of aripiprazole up to the maximum approved adult dose (30 mg/d) in children and adolescents (aged 10-17 years) preferentially with primary psychiatric diagnoses of a bipolar or schizophrenia spectrum disorder. During a dose-escalation phase, patients received aripiprazole for up to 12 days using forced titration to achieve doses of 20, 25, or 30 mg/d. In the subsequent fixed-dose phase, patients received the maximum dose for that cohort for an additional 14 days. Tolerability in each fixed-dose cohort was assessed by measures including evaluation of spontaneously reported adverse events (AEs) and vital signs. If 4 of 6 patients tolerated the maximum dose for the cohort, the dose was considered tolerated, and enrollment in the next dose level began. Of 21 enrolled patients, 17 completed the fixed-dose phase. Aripiprazole treatment was generally well tolerated, with criteria for tolerability met for all doses tested. All patients experienced at least 1 AE, none of which met the regulatory criteria for a serious AE. There were no deaths or clinically relevant changes in vital signs or weight. Aripiprazole PK seemed to be linear across the tested dose range and was comparable with previous PK observations in adults. This study provides information regarding the tolerability and PK of aripiprazole up to the maximum adult dose in children and adolescents. These data provided support for exploration of a 30-mg/d dose in child/adolescent schizophrenia and bipolar disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e31817dd520

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 66

Metadata

Authors
Findling, R. L., Kauffman, R. E., Sallee, F. R., Carson, W. H., Nyilas, M., Mallikaarjun, S., Shoaf, S. E., Forbes, R. A., Boulton, D. W., & Pikalov, A.
Venue
Journal of Clinical Psychopharmacology
Published
2008-08
Volume
28
Issue
4
Pages
441-446
ISSN
0271-0749 (ISSN-L)
OpenAlex
W1988024999
Cited by
66
References
1
FWCI
3.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tolerability and Pharmacokinetics of Aripiprazole in Children and Adolescents With Psychiatric Disorders: An Open-Label, Dose-Escalation Study. https://app.cochat.ai/papers/10.1097/jcp.0b013e31817dd520
The paper
Findling, R. L., Kauffman, R. E., Sallee, F. R., Carson, W. H., Nyilas, M., Mallikaarjun, S., Shoaf, S. E., Forbes, R. A., Boulton, D. W., & Pikalov, A. (2008). Tolerability and Pharmacokinetics of Aripiprazole in Children and Adolescents With Psychiatric Disorders: An Open-Label, Dose-Escalation Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31817dd520

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.